BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 21213113)

  • 1. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension.
    Berzigotti A; Rossi V; Tiani C; Pierpaoli L; Zappoli P; Riili A; Serra C; Andreone P; Morelli MC; Golfieri R; Rossi C; Magalotti D; Zoli M
    J Gastroenterol; 2011 May; 46(5):687-95. PubMed ID: 21213113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score.
    Kang SH; Jeong WK; Baik SK; Cha SH; Kim MY
    J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):860-870. PubMed ID: 30371017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
    Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
    Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
    Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
    Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
    Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
    World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India.
    Kumar A; Khan NM; Anikhindi SA; Sharma P; Bansal N; Singla V; Arora A
    World J Gastroenterol; 2017 Jan; 23(4):687-696. PubMed ID: 28216976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varices on computed tomography are surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patients.
    Lee DH; Ahn JH; Chung JW; Kim YJ; Cha SW; Kim MY; Baik SK
    J Gastroenterol Hepatol; 2019 Feb; 34(2):450-457. PubMed ID: 29900587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
    Paternostro R; Kwanten WJ; Hofer BS; Semmler G; Bagdadi A; Luzko I; Hernández-Gea V; Graupera I; García-Pagán JC; Saltini D; Indulti F; Schepis F; Moga L; Rautou PE; Llop E; Téllez L; Albillos A; Fortea JI; Puente A; Tosetti G; Primignani M; Zipprich A; Vuille-Lessard E; Berzigotti A; Taru MG; Taru V; Procopet B; Jansen C; Praktiknjo M; Gu W; Trebicka J; Ibanez-Samaniego L; Bañares R; Rivera-Esteban J; Pericas JM; Genesca J; Alvarado E; Villanueva C; Larrue H; Bureau C; Laleman W; Ardevol A; Masnou H; Vanwolleghem T; Trauner M; Mandorfer M; Francque S; Reiberger T;
    J Hepatol; 2024 May; ():. PubMed ID: 38823501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
    Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
    World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Evaluation and Prognosis.
    Hernández-Gea V; Berzigotti A
    Dig Dis; 2015; 33(4):515-23. PubMed ID: 26159268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive tests for clinically significant portal hypertension after HCV cure.
    Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
    J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
    Bosch J; Chung C; Carrasco-Zevallos OM; Harrison SA; Abdelmalek MF; Shiffman ML; Rockey DC; Shanis Z; Juyal D; Pokkalla H; Le QH; Resnick M; Montalto M; Beck AH; Wapinski I; Han L; Jia C; Goodman Z; Afdhal N; Myers RP; Sanyal AJ
    Hepatology; 2021 Dec; 74(6):3146-3160. PubMed ID: 34333790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
    Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
    Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients.
    Kim TY; Jeong WK; Sohn JH; Kim J; Kim MY; Kim Y
    Liver Int; 2015 Nov; 35(11):2416-24. PubMed ID: 25875718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg.
    Jindal A; Sarin SK; Kumar M; Kumar G
    Dig Dis Sci; 2022 Nov; 67(11):5280-5289. PubMed ID: 35113276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.